دورية أكاديمية
أعرض في EDS

Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study.

التفاصيل البيبلوغرافية
العنوان: Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study.
المؤلفون: Ambreen A; Department of Microbiology, Gulab Devi Hospital, Lahore, Pakistan.; Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Defence Road Campus, Lahore, Pakistan., Tahseen S; National TB Reference Laboratory, National TB Control Program, Islamabad, Pakistan.; The Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Wali A; The Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway., Jamil M; Department of Tuberculosis and Chest Medicine, Gulab Devi Hospital, Lahore, Pakistan., Naqvi SZH; Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Defence Road Campus, Lahore, Pakistan., Safdar N; Social and Health Inequalities Network (SHINe), a not for Profit, Non-Government Organization, Sindh, Pakistan., Mustafa T; The Centre for International Health, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.; Department of Thoracic medicine, Haukeland University Hospital, Bergen, Norway.
المصدر: PloS one [PLoS One] 2021 Nov 12; Vol. 16 (11), pp. e0259801. Date of Electronic Publication: 2021 Nov 12 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Antitubercular Agents*/therapeutic use, Adolescent ; Adult ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Pakistan/epidemiology ; Prospective Studies ; Treatment Outcome ; Tuberculosis/drug therapy ; Tuberculosis/epidemiology
مستخلص: The optimal duration of treatment in different forms of extrapulmonary tuberculosis (EPTB) is not clearly defined. This study aimed to identify predictors of slow clinical response and extended anti-TB treatment in EPTB patients. Socio-demographic, clinical, and microbiological characteristics of EPTB patients registered for anti-TB treatment at a tertiary care hospital, were analysed for identification of predictors of extended treatment. A total of 251 patients (137 lymphadenitis, and 114 pleuritis) were included in the analysis. Treatment was extended to more than 6 months in 58/251 (23%) patients. In the multivariate regression analysis, culture-positive EPTB (p = 0.007) [OR (95% CI) = 3.81 (1.43, 10.11)], history of diabetes (p = 0.014) [OR (95% CI) = 25.18 (1.94, 325.83)], smokeless tobacco use (p = 0.002) [OR (95% CI) = 17.69 (2.80, 111.72)], and slow regression of local signs and symptoms after 2 months of treatment (p < 0.001) [OR (95% CI) = 17.09 [(5.79, 50.39)] were seen to be significantly associated with treatment extension. Identification of predictors of extended treatment can help clinical decisions regarding optimal duration of treatment. Further studies are needed to identify subgroups of EPTB patients who can benefit from a shorter or longer treatment regimen.
Competing Interests: The authors have declared that no competing interests exist.
References: Tuberculosis (Edinb). 2018 Dec;113:26-29. (PMID: 30514510)
Int J Clin Pract. 2007 Feb;61(2):231-5. (PMID: 17166185)
Lancet. 2002 Aug 17;360(9332):528-34. (PMID: 12241657)
Int J Tuberc Lung Dis. 2019 Aug 1;23(8):900-906. (PMID: 31533879)
Lancet Infect Dis. 2009 Mar;9(3):162-72. (PMID: 19246020)
Chest. 2015 Feb;147(2):520-528. (PMID: 25255302)
Biomed Res Int. 2016;2016:7273935. (PMID: 27642601)
BMC Infect Dis. 2019 Oct 30;19(1):923. (PMID: 31666021)
PLoS One. 2016 Feb 26;11(2):e0150560. (PMID: 26918458)
BMC Infect Dis. 2019 Aug 5;19(1):691. (PMID: 31382889)
Am J Respir Crit Care Med. 2004 Nov 15;170(10):1124-30. (PMID: 15374844)
Thorax. 2017 Mar;72(3):263-270. (PMID: 27553224)
Front Microbiol. 2015 Jun 23;6:641. (PMID: 26157437)
Int J Tuberc Lung Dis. 2010 May;14(5):560-70. (PMID: 20392348)
Am J Respir Crit Care Med. 2006 Aug 1;174(3):344-8. (PMID: 16709935)
J Diabetes Complications. 2014 Mar-Apr;28(2):162-5. (PMID: 24461545)
Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63. (PMID: 19542476)
Nat Med. 2018 Nov;24(11):1708-1715. (PMID: 30397355)
BMC Infect Dis. 2019 May 16;19(1):426. (PMID: 31096926)
Bull World Health Organ. 2015 Jun 1;93(6):390-9. (PMID: 26240460)
Trials. 2018 Apr 19;19(1):237. (PMID: 29673395)
J Pharm Policy Pract. 2020 Jul 24;13:35. (PMID: 32724657)
Nat Rev Drug Discov. 2013 May;12(5):388-404. (PMID: 23629506)
PLoS One. 2011 Apr 08;6(4):e18474. (PMID: 21494617)
Tuberc Res Treat. 2015;2015:609083. (PMID: 25653874)
Thorax. 2020 Jul;75(7):606-608. (PMID: 32354738)
PLoS One. 2012;7(4):e35948. (PMID: 22545150)
Thorax. 2002 Nov;57(11):964-6. (PMID: 12403879)
Nat Med. 2018 Nov;24(11):1639-1641. (PMID: 30401868)
Respir Med. 2014 Apr;108(4):654-9. (PMID: 24518046)
Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. (PMID: 12588714)
Trop Doct. 2003 Jan;33(1):7-11. (PMID: 12568510)
Tubercle. 1979 Dec;60(4):201-10. (PMID: 396701)
Expert Rev Respir Med. 2021 Jul;15(7):931-948. (PMID: 33966561)
المشرفين على المادة: 0 (Antitubercular Agents)
تواريخ الأحداث: Date Created: 20211112 Date Completed: 20240725 Latest Revision: 20240725
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC8589173
DOI: 10.1371/journal.pone.0259801
PMID: 34767601
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0259801